Copy to clipboard 
Integrity Implants and Fusion Robotics have consummated a merger combining the two companies. The combined company will be re-branded as Accelus and is uniquely positioned to accelerate the adoption of minimally invasive surgery as the standard of care in spine.
Although the benefits of MIS have been recognized for decades, broad adoption in the spine market is still constrained relative to other orthopedic and interventional procedures. The combination of Fusion Robotics’ efficient, compact and scalable robot with Integrity Implant’s unique Adaptive Geometry implants will enable the rapid acceleration of MIS adoption.
Integrity Implants’ flagship FlareHawk® Lumbar Interbody Fusion Device received FDA clearance in 2016 and CE mark approval in 2021, and to date more than 10,500 FlareHawk devices have been implanted in more than 8,000 patients. Integrity Implants also holds FDA clearances for its LineSider® Spinal System, FlareHawk TiHawk™ Interbody Fusion System and Toro™-L Interbody Fusion System. Fusion Robotics received a 510(k) clearance for its initial product offering and started performing spine procedures in the U.S. market earlier this year.
Accelus’ corporate office, R&D, distribution and Accelus Clinical Education (ACE) surgeon training facility will be headquartered in Palm Beach Gardens, Fla. Additional ACE labs and R&D centers will be located in Boulder, Colo. and San Diego, Calif.
The company’s Executive Management Team will consist of leaders from both Integrity Implants and Fusion Robotics, who bring decades of experience and leadership across spine, navigation and surgical robotics. Accelus’s Board of Directors will be composed of Fusion Robotics’ founders Alex Lukianov and Brad Clayton; Integrity Implants’ founders Chris Walsh and Wyatt Geist; and current Integrity Implants Directors Nate Ward, Ned Lipes and Paul Birkmeyer.
Source: Accelus
Integrity Implants and Fusion Robotics have consummated a merger combining the two companies. The combined company will be re-branded as Accelus and is uniquely positioned to accelerate the adoption of minimally invasive surgery as the standard of care in spine.
Although the benefits of MIS have been recognized for decades, broad adoption in...
Integrity Implants and Fusion Robotics have consummated a merger combining the two companies. The combined company will be re-branded as Accelus and is uniquely positioned to accelerate the adoption of minimally invasive surgery as the standard of care in spine.
Although the benefits of MIS have been recognized for decades, broad adoption in the spine market is still constrained relative to other orthopedic and interventional procedures. The combination of Fusion Robotics’ efficient, compact and scalable robot with Integrity Implant’s unique Adaptive Geometry implants will enable the rapid acceleration of MIS adoption.
Integrity Implants’ flagship FlareHawk® Lumbar Interbody Fusion Device received FDA clearance in 2016 and CE mark approval in 2021, and to date more than 10,500 FlareHawk devices have been implanted in more than 8,000 patients. Integrity Implants also holds FDA clearances for its LineSider® Spinal System, FlareHawk TiHawk™ Interbody Fusion System and Toro™-L Interbody Fusion System. Fusion Robotics received a 510(k) clearance for its initial product offering and started performing spine procedures in the U.S. market earlier this year.
Accelus’ corporate office, R&D, distribution and Accelus Clinical Education (ACE) surgeon training facility will be headquartered in Palm Beach Gardens, Fla. Additional ACE labs and R&D centers will be located in Boulder, Colo. and San Diego, Calif.
The company’s Executive Management Team will consist of leaders from both Integrity Implants and Fusion Robotics, who bring decades of experience and leadership across spine, navigation and surgical robotics. Accelus’s Board of Directors will be composed of Fusion Robotics’ founders Alex Lukianov and Brad Clayton; Integrity Implants’ founders Chris Walsh and Wyatt Geist; and current Integrity Implants Directors Nate Ward, Ned Lipes and Paul Birkmeyer.
Source: Accelus
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
